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Abstract: Takotsubo cardiomyopathy (TCM) represents an acute systolic left ventricular dysfunction
typically triggered by severe psychological or physical stress. Oncological patients due to emotional
distress of the diagnosis, proinflammatory and prothrombotic nature of cancer and also physical stress
often following complex anticancer therapies are at high-risk of TCM. Moreover, there are also few reports
of TCM associated with oncological treatment, mostly chemotherapy. Recent data from large registries
indicate a surprisingly high incidence of malignancy in TCM, significant differences in clinical character-
istics and unfavorable short- and long-term clinical outcomes in this specific group of patients.
Therefore, we present two case reports of TCM that occurred during active anticancer therapy. Both
women were admitted with suspicion of acute coronary syndrome. The first patient underwent mastect-
omy two years before due to hormone receptor-positive breast cancer and on admission she was during
adjuvant hormonotherapy with tamoxifen. The admission of the second patient was preceded by fifteen
fractions of adjuvant external beam radiotherapy due to intermediate-risk endometrial cancer after radical
hysterectomy. Based on coronary angiography type I of acute coronary syndrome was excluded. Both
patients negated stressful situations in the period immediately before the symptoms onset. Within hospital
course baseline apical ballooning observed in both cases fully recovered and enabled subsequent comple-
tion of oncological treatment in accordance with adopted treatment protocols without recurrence of TCM.
To our knowledge, presented cases are the first reports showing direct relationship between TCM and
adjuvant hormonotherapy with tamoxifen or pelvic radiotherapy.
Keywords: takotsubo cardiomyopathy, acute coronary syndrome, hormonotherapy, radiotherapy, cardio-
oncology.
Introduction
Contemporarily cardiovascular and neoplastic diseases constitute the leading causes of
death all over the world. Cardiovascular complications are also an important problem
in cancer patients. The malignancy process and anticancer treatment are dynamically
explored in current medical research. However, together with numerous achievements
in oncology field which lead to higher survival rates, the cardio-oncology interrelation
seems to be crucial for further improvement of the effectiveness of anticancer treat-
ment, prognosis and patients’ quality of life [1, 2].
In recent years takotsubo cardiomyopathy (TCM) has been proposed as one of the
potential cardiac complications in oncological patients. Although, Joy et al. found that
only 1.13% of 122 855 TCM patients had cancer [3], in other studies the prevalence of
such coexistence was much higher (6.7–14.4%) [4, 5]. In a very recent International
Takotsubo Registry (InterTAK) [6] malignancy was found in 16.6% of 1604 TCM
patients. The most frequent type of malignancy was breast cancer, followed by tumors
of gastrointestinal system, respiratory tract and internal sex organs. Long-term mor-
tality was higher in TCM patients with malignancy without impact on short-term
outcomes. In the subanalysis limited to oncological patients, long-term mortality was
comparable between patients with TCM and acute coronary syndrome (ACS) [6].
Traditionally, the etiology of TCM is associated with severe psychological or
physical stress [7]. Due to this fact it is named also as ‘stress cardiomyopathy’ or
‘broken heart syndrome’ with proven increased sympathetic stimulation and high
catecholamines concentration. Also different mechanisms involved in TCM were
proposed including endothelial dysfunction, severe vasospasm, estrogens deprivation
or inflammatory activation [8]. However, the cause-effect relationships between TCM
and malignancy remain unclear. In oncological patients, the TCM development might
be the result of prolonged stressful situations, mostly associated with diagnosis of
malignancy and inflammatory system activation as a result of tumor development
or use of anticancer treatment. A review of the literature by Coen et al. indicates
5-fluorouracil as the most common molecule associated with TCM [9].
Despite the high proportion of post-menopausal women within TCM patients,
none of the existing reports pointed sexual hormone deprivation during antiestrogen
therapy with tamoxifen — standard treatment in hormone receptor-positive breast
cancer — as a TCM cause. Surprisingly, although the radiotherapy is well-documented
cardiovascular risk factor [1], we found in literature only one case report of thoracic
region radiotherapy that induced TCM [10]. Therefore we sought to present two cases
of co-occurrence of TCM and cancer in women, first during antiestrogen course with
tamoxifen and second during pelvic radiotherapy. The report was prepared as the part
of a project that was complied with the Declaration of Helsinki and was approved by
the local Ethics Committee (Consent No. 1072.6120.59.2018). Written informed con-
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sent was obtained from patients for the publication of the case reports and potentially-
identifying information and images.
Case reports
Case 1
A 76-year-old woman with arterial hypertension and hypercholesterolemia was ad-
mitted with suspicion of ACS. Two years before she underwent resection of hormone
receptor-positive left breast cancer followed by the adjuvant hormonotherapy with
tamoxifen according to the current guidelines [11] (Fig. 1). ECG on admission re-
vealed left axis deviation, the prolonged QT interval of 0.48 s, ST-segment elevation in
III, aVF, V4-6 leads and flattened T wave in aVL and V1-2. All cardiac necrosis
markers were elevated at baseline including isoenzyme MB of creatine kinase of 75
IU/L (upper limit of normal (ULN) <24 IU/L) and troponin I of 9.85 ng/mL (ULN
<0.1 ng/mL). Immediately performed coronary angiography showed normal epicardial
segments, with narrow distal part of left anterior descending artery [12, 13] (Fig. 2),
while left ventricular (LV) angiography and transthoracic echocardiography (TTE)
showed abnormal ballooning of apical segments with decreased ejection fraction up
to 40% and hypertrophic intraventricular septum with obstruction of left ventricular
outflow tract [14] (Fig. 3). Myocardial perfusion scintigraphy showed irreversible
defect of technetium-99m uptake in apex and small reversible defect in periapical
segments. The laboratory tests for pheochromocytoma including vanillylmandelic
acid, metanephrine, normetanephrine and 3-methoxytyramine were unremarkable.
Fig. 1. Time course of oncological treatment and the occurrence of takotsubo cardiomyopathy in both
patients.
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Fig. 2. Normal epicardial coronary arteries with narrow distal part of left anterior descending artery. First
case.
Fig. 3. Ventriculography and transthoracic echocardiography showing a typical ballooning of apex and
periapical segments of left ventricle. First case.
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Typical variant of TCM has been diagnosed according to the current criteria [8]. Apart
from oncological treatment, our patient did not report any factors that could trigger
TCM, therefore decision about the temporary withhold of oncological treatment was
made (Fig. 1) with excellent effect and complete LV recovery in TTE. After 10 days
from the onset of symptoms, tamoxifen therapy was resumed. The patient without any
symptoms was discharged with detailed further follow-up plan [15]. After discharge,
the patient has continued adjuvant hormonotherapy with tamoxifen up to 5 years
without recurrence of TCM (Fig. 1).
Case 2
A 75-year old woman with arterial hypertension, hypercholesterolemia, impaired
fasting glucose and obesity (body mass index of 31.6 kg/m2) was also admitted with
suspicion of ACS. She had a history of radical hysterectomy with appendages due to
intermediate-risk endometrial cancer followed by adjuvant radiotherapy 5 days a week
for three weeks (30.0 Gy in 15 fractions) [16] (Fig. 1). In ECG on admission we found
left axis deviation, PQ interval lasted 0.2 s and inversed T wave in V2-6 leads. The
laboratory tests revealed normal level of isoenzyme MB of creatine kinase (19 U/l) but
elevated troponin T concentration of 0.178 ng/mL (ULN <0.014 ng/mL). The coron-
ary angiography showed normal, slightly tortuous epicardial arteries [12, 13] (Fig. 4),
while TTE showed dyskinetic periapical ballooning of left ventricle (Fig. 5) with
preserved global ejection fraction of about 50% [14]. The laboratory tests for pheo-
chromocytoma were insignificant. Also in this case, the diagnosis of typical variant of
TCM was diagnosed. The patient denied any stressful factor other than oncological
treatment in the period preceding symptoms onset. During the hospital course com-
plete recovery of left ventricular function was observed. After discharge, the patient
Fig. 4. Normal, tortuous epicardial coronary arteries. Second case.
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completed adjuvant radiotherapy in accordance with adopted treatment protocol
(additional 8 fractions) without recurrence of TCM (Fig. 1).
Discussion
The cases documented in this report exemplify the occurrence of typical variant of
TCM in patients with neoplastic diseases. Moreover, they reflect the first well-docu-
mented cases of co-occurrence of TCM with tamoxifen hormonotherapy or pelvic
radiotherapy. In recent years, the direct association between malignancy and non-
oncological comorbidities and their impact on outcomes have met with significant
interest, especially among cardiovascular diseases [1, 17–19]. Also, studies on the
relationship between TCM and neoplastic diseases have recently gathered the novel
findings [3–7]. However, neither tamoxifen nor pelvic radiotherapy were pointed in
current literature as TCM trigger. Importantly, in both presented patients the onco-
logical therapy was resumed with satisfying outcomes despite the fact that the safety of
anticancer therapy continuation in TCM survivors is still uncertain.
According to the recent data, the prevalence of cancer has been estimated between
1.1–16.6% of TCM patients [3–6]. The conclusions from the available studies lead to
the recognition of these patients as a high-risk group with undoubtedly unfavorable
prognosis. The InterTAK Registry indicates that TCM patients with malignancy re-
quired more frequently acute cardiac care (P = 0.007), more often invasive respiratory
support (P = 0.002) and had higher long-term mortality (P <0.001) than others [6]. In
turn, Joy et al. [3] showed higher incidence of in-hospital complications like tracheost-
omy or mechanical ventilation, higher in-hospital mortality (13.8 vs 2.9%, P <0.0001),
Fig. 5. Left ventricular contractility with slightly dyskinetic apical segments visualized with transthoracic
echocardiography. Second case.
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longer in-hospital stay (7 vs 4 days, P <0.0001) and higher total charges of hospitaliza-
tion (P <0.0001) associated with TCM cancer patients. A recent meta-analysis by
Brunetti et al. [4] confirmed previous findings of worse prognosis of malignancy-
related TCM survivors expressed as increased risk of in-hospital events (RR 2.08, 95%
CI 1.50–2.87, P <0.01) and follow-up adverse events (RR 3.30, 95% CI 3.09–3.51,
P <0.01) as compared to TCM patients without cancer.
The unfavorable in-hospital and long-term outcomes in TCM patients with cancer
make that discussion about this coincidence mechanism and subsequent prevention
seems of vital importance. As mentioned above, the significance of stress in TCM
development is well-documented [7, 8]. Cancer is a known trigger for strong emo-
tional impulses, such as stress, fear or anxiety associated with diagnosis and treatment
[20]. The excessive release of catecholamine as a result of high sympathetic stimula-
tion is thought to cause microvascular dysfunction as well as occasional epicardial
vasospasm [8]. The hypothesis of transient coronary artery blood flow impairment
also in our breast cancer patient is supported by the result of scintigraphy. The vast
majority of TCM survivors are post-menopausal women [7]. In this specific popula-
tion significant decrease of estrogen level might be a potential explanation of catecho-
lamine-mediated vasoconstriction [21]. The suggested mechanisms of cardiotoxic
effects of estrogen deprivation are associated with reduction of endothelial nitric oxide
synthase activity and promotion of endothelial apoptosis in response to vascular
injuries [22]. As it has been emphasized in our report, the first presented patient
was not only post-menopausal women but she additionally was treated with anties-
trogen agent tamoxifen. The concentrations of sexual hormones could be extremely
low in such patients and their deficiency might promote the development of TCM. On
the other hand, there is evidence that tamoxifen improves endothelial function [23]
and decreases the risk of myocardial infarction (RR 0.62; 95% CI, 0.41–0.93) [24] in
contrast to anticancer agents with previously demonstrated relationship with TCM
[9]. It is possible that these opposing properties of tamoxifen led to the lack of
a similar clinical case presentation in the literature so far.
The association of radiotherapy and TCM occurrence was previously reported
once in patient with breast cancer [10]. In the current report the second patient
underwent pelvic radiotherapy. However, due to the difference of irradiated region,
the another mechanisms probably led to TCM occurrence in both cases. An irradia-
tion of a supradiaphragm region has been suggested as cardiovascular risk factor in
numerous studies and pointed in last cardio-oncological guidelines of the European
Society of Cardiology [1]. Recent studies provide arguments that endometrial cancer
radiotherapy also increases the cardiovascular risk of thromboembolism (HR 2.07,
99% CI 1.57–2.72), pulmonary heart diseases (HR 1.74, 99% CI 1.26–2.40) or atrial
fibrillation (HR 1.50, 99% CI 1.07–2.11) [25]. This increased thromboembolic risk in
TCM patients may be associated with impaired perfusion of coronary microcircula-
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tion [26–28]. Also our patient had slow epicardial flow and reduced myocardial
perfusion [29, 30].
In case of patients with malignancy complicated by TCM, the issue of anticancer
therapy continuation remains a clinical challenge. Coen’s et al. [9] indicated that in
majority of patients anticancer treatment was changed and only one third of patients
who resumed the prior treatment safely completed therapeutic protocol. In our cases
the initial anticancer therapy was successfully completed. However, the decision of
protocol completion after TCM occurrence remains questionable. In case of our first
patient, the tamoxifen protocol continuation up to five years is clearly recommended
in current guidelines due to the better prognosis documented by Early Breast Cancer
Trialists’ Collaborative Group. The significant reduction of 15-years breast cancer
recurrence (P <0.001) and mortality (P = 0.01) in 5-years tamoxifen group as com-
pared with 1–2-years tamoxifen protocols have been noticed [31]. Discontinuation of
treatment at the time of TCM occurrence in our patient would worsen her long-term
prognosis. Similarly, the completed adjuvant radiotherapy protocol significantly
increased overall survival of patients with stage IC/grade 1 (P <0.001) and stage
IC/grades 3 and 4 (P <0.001) of endometrial carcinoma [32]. Further prospective
studies are required to provide reliable consensus of anticancer regimen resumption
in TCM survivors.
Conclusions
TCM is a possible cardiovascular complication of oncological treatment with evi-
denced serious prognosis. Despite the high prevalence of malignancy in TCM indi-
viduals, the pathogenesis of TCM and its relationship with cancer and anticancer
treatment is still not fully elucidated. As shown above, tamoxifen as well as pelvic
radiotherapy are a possible novel triggers of TCM that was fully reversible and was not
a contraindication for further completion of anticancer treatment protocols.
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